【摘要】 目的:探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)原发部位和临床预后与免疫分型的关系。方法:收集经病理证实的DLBCL病检存档石蜡包埋组织标本53例,应用组织芯片免疫组化方法通过测定CD10、BCL-6和MUM1的表达,将DLBCL分为GCB型和non-GCB型。结果:经免疫学分型后,GCB型占45.3%(24/53),non-GCB型占54.7%(29/53);原发于淋巴结内23例,其中GCB型14例,non-GCB型9例;原发于淋巴结外30例,GCB型占10例,低于淋巴结内组中所占的比例,二者的差异有统计学意义(P<0.05);完全缓解(CR)的DLBCL患者中,GCB型17例,Non-GCB型12例,两种分型的缓解率有显著性差异(P<0.05);生存分析显示GCB型患者与non-GCB型存在明显的差异,GCB患者的生存期长于non-GCB患者。结论:53例DLBCL中,non-GCB型DLBCL在结外的发生率显著高于结内,原发于结外患者多数为non-GCB型;GCB型DLBCL患者的预后明显优于non-GCB型。更多还原

【Abstract】 Objective:To study the relationship between primary site and the prognosis by immunophenotyping 53 DLBCL samples and try to find evidence for clinical treatment and prognosis evaluation. Methods:53 cases of DLBCL were included in this study. By Using tissue microarray immunohistochemistry, the expression of CD10、BCL-6 and MUM1 on the cell surface of the samples were detected and the pathologic types of DLBCL were thus be subdivided into GCB and non-GCB groups. Results; Among 53 DLBCL cases, non-GCB and GCB cases took the percentage of 54.7% and 45.3% respectively. The incidence of lymphoma originating extranodally exceeded that of originating nodally (30/53 vs. 23/53); GCB subtype accounted for 33.3% (10/30) and 60.9% (14/23) in the groups of extranodal and nodal origination respectively and the difference was statistically significant (P <0.05) ; Among all 29 CR cases, subtype GCB and non-GCB accounted for 70.8% (17/29) and 41.3% (12/29) respectively and the difference was also statistically significant (P<0.05) ; The survival analysis showed the overall survival of GCB cases was much better than that of non-GCB cases. Conclusion; The study showed that the GCB subtype cases represented a longer survival period than the non-GCB subtype cases did. And the incidence rate of extranodal originating cases was significantly higher than that of nodal originating ones.更多还原